



## INNOVATION Kyoto 2016 LPS Completes Follow-On Strategic Investment in Drawbridge Health

**Kyoto, Japan, October 27, 2020** – INNOVATION Kyoto 2016 Limited Liability Partnership ("KYOTO-iCAP 1<sup>st</sup> Fund"), and Kyoto University Innovation Capital Co., Ltd. (the general partner. Headquarters: Sakyo-ku, Kyoto City; CEO: Ko Kusumi; "KYOTO-iCAP"), today announced it has completed a follow-on strategic investment in Drawbridge Health Inc. (Headquarters: Menlo Park, CA, U.S.; CEO: Lee McCracken; "Drawbridge"). Participants in the financing include Sumitomo Dainippon Pharma and TOHO Holdings Co., Ltd.. At the same time, Sumitomo Dainippon Pharma has a collaborative research and development agreement with Drawbridge.

Drawbridge is a healthcare technology company that has developed the OneDraw™ Blood Collection Device, a blood sampling solution which enables simplified collection and transportation of dried blood samples for clinical testing. The OneDraw Blood Collection Device, which is the enabling technology for the OneDraw A1C Test System, has received 510(k) clearance from the U.S. FDA and completed the European CE mark process. OneDraw is designed to address the painful experience associated with traditional blood collection and to reduce the barriers to obtaining a blood sample, providing an easy way for healthcare providers to collect samples anywhere and anytime, without requiring specialized training.

Drawbridge has been collaborating with Kyoto University Professor Nobuya Inagaki, M.D., Ph.D., Chairman of the Department of Diabetes, Endocrinology and Nutrition, and Assistant Professor Kaori Ikeda, M.D., Ph.D., to advance the research and development of the technology, which will enable self-management at home and telemedicine for monitoring and management of diabetes and other lifestyle diseases in Japan. KYOTO-iCAP anticipates that Drawbridge's technology will improve human healthcare both in Japan and all over the world.







FDA cleared in 2019, the OneDraw A1C Test System is intended for the collection and stabilization of blood and measurement of HbA1c levels for monitoring the long-term control of blood sugar (glucose) in adults with diabetes.

## **About Drawbridge Health**

Founded in 2015 by GE Ventures and GE Healthcare, Drawbridge Health is a healthcare technology company focused on reinventing the blood draw experience, enabling comfortable convenient blood sample collection anytime and anywhere. By integrating engineering, chemistries, and modular design, Drawbridge Health has developed a people-friendly system for collecting and stabilizing blood samples, opening new doors to enable access to important health information. For more information, please visit www.drawbridgehealth.com.

## About Kyoto University Innovation Capital Co., Ltd. ("Kyoto iCAP")

Kyoto iCAP is a wholly owned subsidiary of Kyoto University established in December 2014. Its purpose is to provide investment and support to companies founded by researchers belonging to Kyoto University (including spin-offs from joint research companies) for commercializing knowledge (including research results, technology, etc.). The KYOTO-iCAP 1st Fund was created from a 16-billion-yen capital contribution from Kyoto University and private financial institutions, in January 2016. KYOTO-iCAP is a general partner of the Fund. The fund management period is 15 years, that enables KYOTO-iCAP to support Kyoto University-originated ventures with long-term and to provide equity from the seed stage to practical application. The university is one of the top research institutions in Asia.

## [Contact Information]

Kyoto University Innovation Capital Co., Ltd.

36-1 Yoshida Honmachi, Sakyo-ku, Kyoto 606-8317 Japan

Kyoto University International Science Innovation Building, East Building, 4th Floor

Head of Media Relations: Osami Kono

Tel: +81-(0)75-753-7588, Fax: +81-(0)75-753-7592





Email: info@kyoto-unicap.co.jp

Drawbridge Health Inc. 1455 Adams Dr, Suite 2010 Menlo Park, CA 94025 Eddy Garcia

Emai: egarcia@dbhealth.com